Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(1)
•••
Comment by JohnEnglishon Mar 18, 2015 12:03pm
42 Views
Post# 23533987

RE:RE:RE:RE:RE:Worth every penny!!

RE:RE:RE:RE:RE:Worth every penny!!It's not hard to keep a browser window open and set it to refresh to see new replies.

It's sad that people here are so cynical and paranoid to think that everyone must have some sort of agenda. Honestly, the whole point of a discussion forum is to discuss; present various opinions and explain why you agree or disagree with them. Simply saying "This stock will go up/down and if you disagree you must be a pumper/basher with an agenda." is simply not productive to anyone. I personally think it says more about those who point and make accusations when something is posted that contridicts their stated opinion. 

I keep saying it but I have no shares of Antibe, I've never owned any, and I've never been employed by them in any way. I also have never had any other Stockhouse accounts. 

No where have I ever said that I want the stock to go down. I've never even posted what I think is bad or negative news. I've simply pointed out what M|Partners publically stated in their note. I don't see how that could be construed as bashing or an attempt to apply downward pressure on the stock.

I'm not trying to convince anyone, people will believe what they want. I am simply stating the truth in so far as these allegations regarding my supposed attempt to push the stock price down.

I also enjoy the conversation and the back and forth.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities